Direct drop of 40,000 yuan 257 kinds of supplies the lowest price announced in the country

On September 8, Heilongjiang Public Resources Trading Network released the "Public Notice on Adjusting the Price Information of High-Value Medical Supplies" and announced the results of the price reduction of 257 kinds of consumables.
According to Cypress Blue equipment combing, this high-value supplies price adjustment involves electrophysiology, non-vascular implants, joints, oral, neurosurgery, in vitro circulation and blood purification, vascular intervention and other consumables, involving Belang Medical, Poco, Fesenyus, Shanghai minimally invasive, Xeronic and other well-known domestic and foreign equipment products.
Among them, the maximum price reduction of 54.55 percent, there are 8 kinds of consumables price reduction of more than 50%, 6 kinds of consumables price reduction between 40%-50%, 14 kinds of consumables price reduction between 30%-40%, 16 kinds of consumables price reduction between 20%-30%.
such as a skull fixed titanium mesh and screw system of Belang Medical, the price fell from 6600 yuan to 3000 yuan, a decrease of 54.55%; The price of bone repair materials fell 50% from 5,600 yuan to 2,800 yuan, while the artificial crystals controlled by Shanghai Pharmaceuticals fell 34.49 percent from 3,500 yuan to 2,292.99 yuan.
, although the decline is not the highest, but the absolute value of the price reduction of more than 40,000 yuan.
, an implantable pacemaker, dropped from 93,060 yuan to 52,380 yuan, a price reduction of 40,680 yuan, a drop of 43.71 percent.
this decline has been close to or even more than the average decline in belt purchases in some provinces.
August 19 this year, Anhui Provincial Health Insurance Bureau announced that the completion of the province's public medical institutions, the second batch of high-value medical supplies centralized belt procurement bargaining, of which 82 products in the pacemaker category fell by an average of 46.75 percent.
July 31, 2019, the results of the first consumables alliance negotiations in Jiangsu Province were announced, in which pacemakers were negotiated by production enterprises, with the average decline of 15.86 percent and a maximum decrease of 38.13 percent.
Multinational arms companies dominate the hundreds of billions of markets it is understood that pacemakers are implanted into the body of electronic treatment instruments, through the pulse generator to distribute the energy provided by the battery electrical impulses, through the conduction of wire electrodes, stimulate the electrodes contact with the heart muscle, so that the heart agitation and contraction, so as to achieve the treatment of certain arrhythroid arrhythmic disorder caused by cardiac arrhythmic disorders.
market for electrophysiology and pacemakers is not to be underestimated, according to GlobalData analysis, the global cardiac rhythm management market size is expected to reach about $14.3 billion in 2018 and $15.7 billion (about 107.8 billion yuan) in 2020, with a compound annual growth rate of 4.6%.
pacemakers are divided into single-cavity pacemakers, two-cavity pacemakers, three-cavity pacemakers and three-chamber defibrillators.
China Industrial Information Network data show that single-cavity pacemaker for low-end products, domestic prices in 2-3 million yuan, limited efficacy, can maintain the basic needs of patients, but may trigger pacemaker syndrome
three-cavity pacemaker is the most high-end products, the domestic price of about 100,000 yuan, can treat left and right cardiac dissogram caused by heart failure, three-cavity defibrillator is a combination of three-cavity pacemaker and defibrillator, for dilated cardiomyopathy patients have significant efficacy, but the highest price, reached 15-25 million yuan.
according to the 2015 China Cardiovascular Report, bi-cavity pacemakers account for nearly 67% of all types of pacemakers.
the low penetration rate of the domestic market and the majority of the market occupied by multinational arms companies, China Industrial Information Network data show that by 2017, Medtron, St. Jude, Boston Scientific brand occupies more than 80% of the market share.
, it is understood that pacemaker research and development technical barriers are high, until 2009, domestic enterprises only broke the pacemaker's foreign monopoly.
Firestone creation combing shows that Shaanxi Qinming Medical Instruments Co., Ltd. is China's first professional pacemaker business enterprises, in July 2009, it and Xi'an 2312S / M implantable pacemaker developed in cooperation with Xi'an 2312S / M implanted pacemaker successfully obtained a medical device registration certificate, breaking the domestic pacemaker market foreign monopoly.
2010 and 2012, Lepu Medical acquired a total of 75.1% of Qin Ming Medical's shares, becoming the controlling shareholder of Qin Ming Medical, and in 2016, Qin ming Medical officially changed its name to Lepu Medical Electronic Instruments Co., Ltd.